ALNY - Alnylam Pharmaceuticals, Inc.
| Previous Close | 95.21 |
| Open | 95.29 |
| Bid | 93.04 x 800 |
| Ask | 95.00 x 800 |
| Day's Range | 93.36 - 95.57 |
| 52 Week Range | 87.35 - 153.99 |
| Volume | 734,784 |
| Avg. Volume | 876,341 |
| Market Cap | 9.52B |
| Beta | 3.35 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.87 |
| Earnings Date | Nov 5, 2018 - Nov 9, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 144.47 |
- PR Newswire•2 days ago
ALNYLAM INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Alnylam Pharmaceuticals, Inc. To Contact The Firm
NEW YORK , Sept. 20, 2018 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities claims against Alnylam Pharmaceuticals, Inc. ("Alnylam" ...
Markit•3 days agoSee what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals Inc NASDAQ/NGS:ALNY
- ACCESSWIRE•4 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY
NEW YORK, NY / ACCESSWIRE / September 18, 2018 / Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (ALNY). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980. The investigation concerns whether Alnylam and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
- GlobeNewswire•8 days ago
ALNYLAM INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Alnylam Pharmaceuticals, Inc. To Contact The Firm
NEW YORK, Sept. 14, 2018-- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities claims against Alnylam Pharmaceuticals, Inc.. If you invested in Alnylam stock ...
Market Realist•8 days agoWhat Solid Biosciences’ Valuation Trend Indicates
Solid Biosciences (SLDB) incurred a net loss of $17.98 million in the second quarter of 2018, which compares to a net loss of $11.31 million in the second quarter of 2017, translating to a net loss per share of $0.52 in the second quarter of 2018. Its net loss per share was $0.66 in the second quarter of 2017. The decrease in net loss per share was due to an increase in the company’s outstanding shares, which increased from 17.04 million in the second quarter of 2017 to 34.45 million in the second quarter of 2018.
Market Realist•9 days agoWhy Dicerna Pharmaceuticals Stock Rose 7.7% Yesterday
On September 13, Dicerna Pharmaceuticals (DRNA) stock rose 7.71% to $16.62 from its previous day’s close of $15.43. In the trial, Dicerna’s lead drug candidate, DCR-PHXC, showed that it was capable of bringing urinary oxalate levels to a normal or near-normal range in individuals with primary hyperoxaluria type 1 and hyperoxaluria type 2. The company is conducting studies with DCR-PHXC and investigating its potential as a therapy for all forms of hyperoxaluria.
- GlobeNewswire•9 days ago
Alnylam Investigation: Bernstein Liebhard LLP Announces Investigation of Alnylam Pharmaceuticals, Inc. - ALNY
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (ALNY) resulting from allegations that Alnylam and/or its executives may have issued materially misleading business information to the investing public. If you purchased Alnylam securities, and/or would like to discuss your legal rights and options, please visit Alnylam Shareholder Investigation or contact Daniel Sadeh toll free at (877) 779-1414 or dsadeh@bernlieb.com. On September 12, 2018, Nomura/Instinet analyst Christopher Marai stated that a review document released by the U.S. Food and Drug Administration’s (“FDA”) Center for Drug Evaluation and Research “highlights greater risk” with respect to certain trials of Alnylams’ ONPATTRO (patisiran) lipid complex injection, as well as “a limited market opportunity in TTRcardiomyopathy, and a potential platform safety risk.” Specifically, Marai asserted that “[t]he document highlights FDA reviewers’ concerns over cardiac deaths in patients treated with ONPATTRO and suggests that the drug should be limited to patients with polyneuropathy only (i.e., not patients with cardiac manifestations and polyneuropathy).
- Business Wire•9 days ago
Alnylam Announces Publication in Circulation of Exploratory Cardiac Endpoint Data from APOLLO Phase 3 Study of Patisiran
Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today publication of data from exploratory cardiac assessments in the APOLLO Phase 3 study of patisiran, an RNAi therapeutic for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. The results were published online today in the journal Circulation, and showed that patisiran improved markers of cardiomyopathy in patients with hATTR amyloidosis with polyneuropathy.
- PR Newswire•9 days ago
Alnylam Investigation: Bernstein Liebhard LLP Announces Investigation Of Alnylam Pharmaceuticals, Inc. - ALNY
NEW YORK , Sept. 13, 2018 /PRNewswire/ -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of Alnylam ...
- GlobeNewswire•9 days ago
Bragar Eagel & Squire, P.C. is Investigating Alnylam Pharmaceuticals, Inc. on Behalf of Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating potential claims against Alnylam Pharmaceuticals, Inc. (ALNY). Our investigation concerns whether Alnylam has violated the federal securities laws and/or engaged in other unlawful business practices. Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning our investigation into Alnylam Pharmaceuticals, Inc., please go to http://www.bespc.com/alny/. For additional information about Bragar Eagel & Squire, P.C., please go to www.bespc.com.
Market Realist•9 days agoWhat Sarepta Therapeutics’ Valuation Trend Indicates
Sarepta Therapeutics (SRPT) incurred a net loss of $109.27 million in the second quarter of 2018 compared to a net loss of $63.05 million in Q2 2017. Its net loss per share was $1.15 in the second quarter of 2017. Despite the surge in revenues, Sarepta’s net loss widened due to higher operating expenses, which increased from $98.35 million in the second quarter of 2017 to $176.96 million in the second quarter of 2018.
- PR Newswire•10 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY
NEW YORK , Sept. 12, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ: ALNY). ...
- PR Newswire•10 days ago
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alnylam Pharmaceuticals, Inc. (ALNY)
NEW YORK , Sept. 12, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Alnylam Pharmaceuticals, Inc. ("Alnylam" ...
- Motley Fool•15 days ago
Here's Why Dicerna Pharmaceuticals, Inc. Is on a Roller Coaster; Down 18% Yesterday, Up 17% Today
Investors ponder the biotech's secondary offering.
Markit•16 days agoSee what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals Inc NASDAQ/NGS:ALNY
Market Realist•17 days agoHow’s Alkermes Positioned Financially in September?
In the second quarter, Alkermes (ALKS) reported revenues of $304.6 million—compared to $218.8 million in the second quarter of 2017, which reflects ~39% growth year-over-year. In the second quarter, Alkermes generated revenues of $128.2 million as manufacturing and royalty revenues. Alkermes reported revenues of $109.8 from product sales in the second quarter—compared to $88.7 million in the second quarter of 2017.
Market Realist•17 days agoAlkermes: Analysts’ View in September
Alkermes (ALKS) anticipates the net revenues in fiscal 2018 to be $957.0 million–$1.0 billion. Alkermes estimates the GAAP (generally accepted accounting principle) net income to be -$210.0 million to -$240.0 million, while the GAAP EPS is expected to be -$1.35 to -$1.55. Alkermes expects the non-GAAP net income to be between -$10 million and $20 million. The company also estimates the non-GAAP EPS to be between -$0.06 and $0.12.
- American City Business Journals•19 days ago
What you missed on your summer vacation in Mass. biotech news
Here's a look at the Boston biotech news you missed during your summer vacation: Alnylam gets historic FDA approval for first drug Cambridge's Alnylam Pharmaceuticals (Nasdaq: ALNY) received FDA approval for its first drug on Aug. 10, a first-ever treatment for a rare genetic disease that uses RNA interference to silence genes. The drug treats hereditary ATTR amyloidosis, which causes the liver to protein abnormal proteins that impede nervous system and organ functions. Marketed under the name Onpattro, it's the first RNA interference drug to be approved by the FDA.
- Zacks•22 days ago
Alnylam Gets European Nod for First-Ever RNAi Therapeutic
Alnylam's (ALNY) Onpattro, the first ever RNA interference (RNAi) therapeutic, has been granted marketing authorization by the European Commission.
Markit•24 days agoSee what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals Inc NASDAQ/NGS:ALNY
- Business Wire•24 days ago
Alnylam Receives Approval of ONPATTRO™ (patisiran) in Europe
Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today that the European Commission (EC) has granted marketing authorization for ONPATTRO™ (patisiran) for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adults with stage 1 or stage 2 polyneuropathy. ONPATTRO is based on Nobel Prize-winning science and is the first-ever RNA interference (RNAi) therapeutic to be approved in the European Union.
- Business Wire•25 days ago
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust discovery platform.
- Motley Fool•26 days ago
6 Things Alnylam Investors Need to Know About Pfizer's Next Blockbuster Drug
A successful launch for Alnylam's first drug is far from guaranteed.
Market Realist•26 days agoWhy Alnylam Pharmaceuticals Stock Rose ~16% Yesterday
Yesterday, Alnylam Pharmaceuticals (ALNY) rose ~19% in afternoon trading and closed the day ~16.3% higher than the previous day’s closing price. The rise was triggered by the news of positive phase three study data from Pfizer (PFE) for rival drug tafamidis for the treatment of transthyretin amyloid cardiomyopathy (or ATTR-CM). Alnylam Pharmaceuticals’ ATTR therapy Onpattro (patisiran) was approved by the FDA on August 10, 2018.
- ACCESSWIRE•26 days ago
Today’s Research Reports on Stocks to Watch: Pfizer and Alnylam Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / August 28, 2018 / Pfizer announcing positive study results of its drug tafamidis for transthyretin amyloid cardiomyopathy, sent shares of Alynylam Pharmaceuticals skyrocketing on Monday as the company is developing a drug for a similar disease. Pfizer Inc. shares were down almost 2% on Monday despite Wall Street learning that the company may have a potential blockbuster medicine in its hands. A new study has shown that patients who have a rare condition called transthyretin amyloid cardiomyopathy, which can lead to heart failure, lowered their risk of dying by 30 percent after being treated with Pfizer’s tafamidis.
